Akudugu John, Serafin Antonio, Böhm Lothar
Division of Radiobiology, Department of Medical Imaging and Clinical Oncology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, 7505, South Africa,
J Cancer Res Clin Oncol. 2015 Apr;141(4):627-31. doi: 10.1007/s00432-014-1848-3. Epub 2014 Oct 17.
To assay for uPA and PAI-1 in prostate tissue from 40 patients with prostatic disease and to examine the robustness of the correlation of the uPA/PAI-1 ratio with benign prostatic hyperplasia (BPH) and prostate cancer (PCa), previously identified in a different cohort of 62 patients.
uPA and PAI-1 were extracted from liquid N2 frozen homogenised prostate tissue with TRIS/Triton pH 8.5 buffer and measured by ELISA (FEMTELLE).
The concentration of uPA (mean ± SD) was found to be 0.1177 ± 0.0266 (range 0.0070-0.7200; n = 30) and 0.1092 ± 0.0130 (range 0.0040-0.7800; n = 70) for PCa and BPH patients, respectively. The concentration of PAI-1 was found to be 5.236 ± 0.688 ng/mg protein (range 1.10-15.19; n = 30) and 4.975 ± 0.501 ng/mg protein (range 0.20-25.00; n = 70) for PCa and BPH patients, respectively. The mean uPA/PAI-1 ratio was found to be 0.0479 ± 0.0060 (range 0.0043-0.1200; n = 30) in PCa samples and was significantly higher than BPH samples where the ratio was 0.0332 ± 0.0023 (range 0.0040-0.0860; n = 70) (P = 0.0064). In PCa patients older than 68 years, the uPA/PAI-1 ratio was above 0.050 reaching 0.100 in 73-year-old patients.
Evaluation of 100 patients with prostatic pathologies (70 PCa; 30 BPH) shows the uPA/PAI-1 ratios in PCa patients to be significantly higher than in BPH patients. This is fully consistent with a previous study on 62 patients (16 were PCa; 46 BPH) where the ratios were 0.055 and 0.031 for PCa and BPH patients, respectively (P = 0.0028). In older PCa patients, uPA/PAI-1 ratios tend to be higher.
检测40例前列腺疾病患者前列腺组织中的尿激酶型纤溶酶原激活剂（uPA）和纤溶酶原激活物抑制剂-1（PAI-1），并检验之前在另一组62例患者中发现的uPA/PAI-1比值与良性前列腺增生（BPH）和前列腺癌（PCa）之间相关性的稳健性。
用pH 8.5的TRIS/ Triton缓冲液从液氮冷冻匀浆的前列腺组织中提取uPA和PAI-1，并通过酶联免疫吸附测定法（FEMTELLE）进行检测。
PCa患者和BPH患者的uPA浓度（均值±标准差）分别为0.1177±0.0266（范围0.0070 - 0.7200；n = 30）和0.1092±0.0130（范围0.0040 - 0.7800；n = 70）。PCa患者和BPH患者的PAI-1浓度分别为5.236±0.688 ng/mg蛋白（范围1.10 - 15.19；n = 30）和4.975±0.501 ng/mg蛋白（范围0.20 - 25.00；n = 70）。PCa样本的平均uPA/PAI-1比值为0.0479±0.0060（范围0.0043 - 0.1200；n = 30），显著高于BPH样本，后者的比值为0.0332±0.0023（范围0.0040 - 0.0860；n = 70）（P = 0.0064）。在68岁以上的PCa患者中，uPA/PAI-1比值高于0.050，在73岁患者中达到0.100。
对100例前列腺疾病患者（70例PCa；30例BPH）的评估显示，PCa患者的uPA/PAI-1比值显著高于BPH患者。这与之前对62例患者（16例PCa；46例BPH）的研究完全一致，在该研究中，PCa患者和BPH患者的比值分别为0.055和0.031（P = 0.0028）。在老年PCa患者中，uPA/PAI-1比值往往更高。
